Susquehanna International Group
ABUS icon

Susquehanna International Group’s Arbutus Biopharma ABUS Stock Holding History

Susquehanna International Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$652K Sell
144,900
-328,700
-69% -$1.44M ﹤0.01% 8978
2025
Q4 		$2.28M Buy
473,600
+101,500
+27% +$456K ﹤0.01% 5372
2025
Q3 		$1.69M Buy
372,100
+102,900
+38% +$378K ﹤0.01% 6152
2025
Q2 		$832K Buy
269,200
+203,600
+310% +$676K ﹤0.01% 7921
2025
Q1 		$229K Sell
65,600
-179,000
-73% -$597K ﹤0.01% 10660
2024
Q4 		$800K Sell
244,600
-127,200
-34% -$468K ﹤0.01% 7515
2024
Q3 		$1.43M Buy
371,800
+254,800
+218% +$977K ﹤0.01% 6012
2024
Q2 		$362K Sell
117,000
-1,121,900
-91% -$3.37M ﹤0.01% 9046
2024
Q1 		$3.2M Buy
1,238,900
+1,072,900
+646% +$2.78M ﹤0.01% 4400
2023
Q4 		$415K Buy
166,000
+94,600
+132% +$185K ﹤0.01% 9100
2023
Q3 		$145K Sell
71,400
-36,600
-34% -$76.7K ﹤0.01% 10577
2023
Q2 		$248K Sell
108,000
-232,400
-68% -$605K ﹤0.01% 9827
2023
Q1 		$1.03M Buy
340,400
+205,500
+152% +$580K ﹤0.01% 6732
2022
Q4 		$314K Sell
134,900
-10,300
-7% -$24.6K ﹤0.01% 8979
2022
Q3 		$277K Sell
145,200
-396,200
-73% -$933K ﹤0.01% 9991
2022
Q2 		$1.47M Buy
541,400
+94,000
+21% +$241K ﹤0.01% 5587
2022
Q1 		$1.33M Sell
447,400
-40,400
-8% -$124K ﹤0.01% 6422
2021
Q4 		$1.9M Buy
487,800
+86,800
+22% +$337K ﹤0.01% 5628
2021
Q3 		$1.72M Buy
401,000
+48,100
+14% +$160K ﹤0.01% 6172
2021
Q2 		$1.07M Buy
352,900
+165,500
+88% +$513K ﹤0.01% 7582
2021
Q1 		$624K Sell
187,400
-350,500
-65% -$1.35M ﹤0.01% 8948
2020
Q4 		$1.91M Buy
537,900
+386,200
+255% +$1.35M ﹤0.01% 5202
2020
Q3 		$475K Buy
151,700
+125,000
+468% +$380K ﹤0.01% 7793
2020
Q2 		$49K Buy
26,700
+14,500
+119% +$23.7K ﹤0.01% 9752
2020
Q1 		$12K Sell
12,200
-64,100
-84% -$173K ﹤0.01% 10016
2019
Q4 		$212K Buy
+76,300
New +$123K ﹤0.01% 8668
2019
Q3 		– Sell
-11,100
Closed -$23K – 10078
2019
Q2 		$23K Sell
11,100
-101,800
-90% -$260K ﹤0.01% 9986
2019
Q1 		$404K Buy
112,900
+95,500
+549% +$367K ﹤0.01% 6679
2018
Q4 		$67K Sell
17,400
-15,000
-46% -$73.9K ﹤0.01% 8374
2018
Q3 		$306K Sell
32,400
-40,900
-56% -$406K ﹤0.01% 7444
2018
Q2 		$535K Sell
73,300
-34,400
-32% -$205K ﹤0.01% 6646
2018
Q1 		$539K Buy
107,700
+91,800
+577% +$486K ﹤0.01% 6476
2017
Q4 		$80K Buy
15,900
+1,400
+10% +$8.21K ﹤0.01% 8772
2017
Q3 		$90K Buy
+14,500
New +$62K ﹤0.01% 8391
2017
Q1 		– Sell
-31,700
Closed -$78K – 8816
2016
Q4 		$78K Sell
31,700
-6,500
-17% -$18.9K ﹤0.01% 9172
2016
Q3 		$131K Buy
38,200
+8,900
+30% +$34.8K ﹤0.01% 7831
2016
Q2 		$102K Buy
29,300
+14,100
+93% +$59.7K ﹤0.01% 8011
2016
Q1 		$63K Sell
15,200
-23,000
-60% -$82.2K ﹤0.01% 8601
2015
Q4 		$170K Sell
38,200
-15,100
-28% -$82.8K ﹤0.01% 8547
2015
Q3 		$325K Sell
53,300
-48,800
-48% -$433K ﹤0.01% 7895
2015
Q2 		$1.21M Buy
102,100
+4,300
+4% +$65.4K ﹤0.01% 5789
2015
Q1 		$1.71M Sell
97,800
-92,500
-49% -$1.89M ﹤0.01% 4616
2014
Q4 		$2.88M Sell
190,300
-21,000
-10% -$362K ﹤0.01% 3808
2014
Q3 		$4.47M Buy
211,300
+156,800
+288% +$2.56M ﹤0.01% 3188
2014
Q2 		$712K Buy
+54,500
New +$773K ﹤0.01% 6777

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Susquehanna International Group's ABUS Position: Q1 2026 in Review

Susquehanna International Group increased its Arbutus Biopharma (ABUS) stake by 121% in Q1 2026, buying an estimated $580K and bringing the position to 241,970 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #7663.

Susquehanna International Group first reported a position in ABUS in Q1 2014 and has held it in 40 quarters since. The position peaked at $4.56M in Q3 2014. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Susquehanna International Group held 241,970 shares of Arbutus Biopharma worth $1.09M as of Q1 2026.
  • Susquehanna International Group bought 132,559 Arbutus Biopharma shares in Q1 2026, an estimated $580K.
  • Arbutus Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7663 holding.
  • Susquehanna International Group first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 40 quarters since.
  • Susquehanna International Group's Arbutus Biopharma position peaked at $4.56M in Q3 2014.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.